What's Next: Kamada's Earnings Preview
Kamada (NASDAQ:KMDA) is gearing up to announce its quarterly earnings on Wednesday, 2026-03-11. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Kamada will report an earnings per share (EPS) of $0.08.
The announcement from Kamada is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Performance in Previous Earnings
During the last quarter, the company reported an EPS missed by $0.01, leading to a 0.57% increase in the share price on the subsequent day.
Here's a look at Kamada's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.10 | 0.09 | 0.07 | 0.05 |
| EPS Actual | 0.09 | 0.13 | 0.07 | 0.07 |
| Price Change % | 0.57 | -1.08 | -2.70 | 3.10 |
Stock Performance
Shares of Kamada were trading at $8.98 as of March 09. Over the last 52-week period, shares are up 22.34%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
About Kamada
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Kamada's Financial Performance
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Kamada displayed positive results in 3 months. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 12.63%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Kamada's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.27%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Kamada's ROE excels beyond industry benchmarks, reaching 2.02%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Kamada's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.42% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.04, Kamada adopts a prudent financial strategy, indicating a balanced approach to debt management.
To track all earnings releases for Kamada visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.